Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment
Abstract
Icariin (ICA), the principal flavonoid from Epimedii Folium, aligns with traditional Chinese medicine indications of tonifying kidney-yang and strengthening bone. Prior reviews mostly catalog ICA's preclinical neuroprotective, anti-fibrotic, anti-tumor, and osteoprotective effects, but lack evidence stratification. Here, we establish an evidence-stratified framework to evaluate ICA's structure-activity relationships, pharmacokinetics, and safety profiles, explicitly distinguishing preclinical pharmacological actions from unproven clinical efficacy. We delineate translational barriers including interspecies pharmacokinetic gaps, poor bioavailability, and flawed trial designs, and assess delivery systems to address these limitations. This work bridges traditional Chinese medicine practice with graded modern evidence, providing a translational roadmap to guide ICA's rational clinical development.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.